OncoMatch/Clinical Trials/NCT05317403
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Is NCT05317403 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for acute myeloid leukemia, in relapse.
Treatment: Venetoclax · Azacitadine · Vorinostat · Cytarabine · Fludarabine · Filgrastim — The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Demographics
Lab requirements
Kidney function
Calculated creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine
Liver function
Direct bilirubin < 1.5 x ULN for age or normal, AND ALT < 5 x ULN for age. Hepatic requirements are waived for patients with known or suspected liver involvement by leukemia, with study chair approval.
Cardiac function
Shortening fraction of ≥ 27% OR ejection fraction of ≥ 50%
Adequate renal and hepatic functions as indicated by the following laboratory values: ... Adequate Cardiac Function Defined as: Shortening fraction of ≥ 27% OR ejection fraction of ≥ 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05317403 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages